Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 643-647

  Nomura, Yuya ^a   Nakakura, Shunsuke ^b   Moriwaki, Mitsuyasu ^a   Takahashi, Yasuhiro ^a   Shiraki, Kunihiko ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Saiseikai Gose Hospital   (Japan)

Author keywords

24 hour intraocular pressure; Fluctuation; Normal tension glaucoma; Travatan Z; Travoprost

Indexed keywords

TRAVATAN Z; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; NORMAL TENSION GLAUCOMA; PATIENT MONITORING; PRESSURE MEASUREMENT; RETROSPECTIVE STUDY; TIME; TONOMETER; UNSPECIFIED SIDE EFFECT;

EID: 77956108660     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Article

References (30)

1. Collaborative Normal Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487-497.
2. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498-505.
3. Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(2):205-209.
4. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134-142.
5. Ishida K, Yamamoto T, Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. J Glaucoma. 1998;7(6):372-377.
6. Zeimer RC, Wilensky JT, Gieser DK, Viana MA. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology. 1991;98(1):64-69.
7. Wilensky JT, Gieser DK, Mori MT, Langenberg PW, Zeimer RC. Selftonometry to manage patients with glaucoma and apparently controlled intraocular pressure. Arch Ophthalmol. 1987;105(8):1072-1075.
8. Nakakura S, Nomura Y, Ataka S, Shiraki K. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical anti-glaucoma eye drops. J Glaucoma. 2007;16(2):201-204.
9. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(7):1117-1122.
10. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116(7):1243-1249.
11. Ang A, Reddy MA, Shepstone L, Broadway DC. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol. 2004;88(5):630-634.
12. Ishibashi S, Hirose N, Tawara A, Kubota T. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma. J Glaucoma. 2006;15(5):354-357.
13. Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23(3):385-394.
14. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertention. Ophthalmology. 2006;113(2):239-246.
15. Parrish RK, Palmberg P, Sheu WP; XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703.
16. Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma. 2008;17(1):36-39.
17. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53(1):18-23.
18. Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: A randomised control trial. Br J Ophthalmol. 2008;92(8):1129-1133.
19. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217-222.
20. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103(8):1276-1282.
21. Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AG, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normaltension glaucoma. Br J Ophthalmol. 2008;92(9):1227-1231.
22. Netland PA, Robertson SM, Sullivan EK, et al; Travoprost Study Groups. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertention. Adv Ther. 2003;20(3):149-163.
23. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5):490-496.
24. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-1454.
25. Sung KR, Lee S, Park SB, et al. Twenty-four hour ocular perfusion pressure fluctuation and risk of normal-tension glaucoma progression. Invest Ophthalmol Vis Sci. 2009;50(11):5266-5274.
26. Choi J, Kim KH, Jeong J, Cho HS, Lee CH, Kook MS. Circadian fluctuation of mean ocular perfusion pressure is a consistent risk factor for normal-tension glaucoma. Invest Ophthalmol Vis Sci. 2007;48(1):104-111.
27. Choi J, Jeong J, Cho HS, Kook MS. Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: A risk factor for normal tension glaucoma. Invest Ophthalmol Vis Sci. 2006;47(3):831-836.
28. Costagliola C, Parmeggiani F, Virgili G, et al. Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 2008;246(3):389-396.
29. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: A 6-month clinical trial. Acta Ophthalmol Scand. 2007;85(8):838-843.
30. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circulation IOP, blood pressure, amd calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917-2923.